8 things you missed at ARVO and ACSRS 2016

Bausch + Lomb received approval from the U.S. Food and Drug Administration (FDA) for a number of enhancements to its Trulign Toric IOL calculator.
The FDA approval of the company’s recent enhancements to the Trulign Toric calculator enhancements, which were updated based on direct feedback from customers, will include a number of refinements allowing users to:
• Interface directly with the IOLMaster or Lenstar systems to help facilitate the input of patient data and create a seamless user experience

• Display the make and model of the Crystalens IOL, if a non-toric lens is recommended while displaying the intraocular lens IOL at 90 degrees with no axis of alignment

Bausch + Lomb also announced a collaboration to develop an iPhone and iPad app for cataract surgeons. The app will help surgeons streamline their workflow by delivering patient information and clinical insights as well as IOL options on a single, digital platform at the point of care.

The app will be designed to provide surgeons with access to information that patients have agreed to share, enabling doctors to plan their surgical interventions—including IOL selection—and have the option to view the information on digital devices or display screens during surgery.

The app will be designed to electronically manage patient data across iPhone and iPad while hosting health-related data on IBM Cloud Platform, Bluemix, and relaying customized IOL options to surgeons. The MobileFirst for iOS team, which is part of IBM Global Business Services, will design and develop this custom app for Bausch + Lomb. Bausch + Lomb plans to use the app to collect data over time, resulting in a cognitive app that applies machine-based learning and predictive analytics to deliver real-time insights to surgeons.

By compiling each cataract patient’s information in the app—including IOL calculations, corneal topography and other biometry results as well as lifestyle preferences—surgeons and their staff may generate a comprehensive, integrated profile to help them facilitate IOL selection and procedure planning. Historical surgical data and other patient insights can also be housed within the app to potentially support positive clinical outcomes for future cataract.

Pilot study testing for the new application is expected to begin in late 2016.

“We know that CTRs are an important part of many of our customers’ armamentarium, so we look forward to providing our customers an exceptional CTR that has the significant benefits of a posterior chamber IOL,” says Andy Chang, senior vice president and general manager, U.S. Surgical, Bausch + Lomb.

The company expects to receive FDA approval for the use and commercialization of FortifEYE CTR later this year.

0 Comments

You must be signed in to leave a comment. Registering is fast and free!

All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.